Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19 |
| |
Authors: | Ken Sato Yuichi Yamazaki Toshio Uraoka |
| |
Affiliation: | Ken Sato, Yuichi Yamazaki, Toshio Uraoka, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Gunma, Japan |
| |
Abstract: | Investigational treatments/drugs for coronavirus disease 2019 (COVID-19) have been applied, with repurposed or newly developed drugs, and their effectiveness has been evaluated. Some of these drugs may be hepatotoxic, and each monotherapy or combination therapy may increase the risk of drug-induced liver injury (DILI). We should aim to control dysregulation of liver function, as well as the progression of COVID-19, as much as possible. We discussed the potential risks of investigational treatments/drugs and promising drugs for both COVID-19 and DILI due to investigational treatments/drugs. |
| |
Keywords: | Coronavirus disease 2019 Drug-induced liver injury Cytochrome P450 Drug-drug interaction Drug-disease interaction Cytokine |
|
| 点击此处可从《World journal of gastroenterology : WJG》浏览原始摘要信息 |
|